dc.creatorMorari, EC
dc.creatorSilva, JR
dc.creatorGuilhen, ACT
dc.creatorCunha, LL
dc.creatorMarcello, MA
dc.creatorSoares, FA
dc.creatorVassallo, J
dc.creatorWard, LS
dc.date2010
dc.dateDEC
dc.date2014-11-14T06:03:21Z
dc.date2015-11-26T17:13:26Z
dc.date2014-11-14T06:03:21Z
dc.date2015-11-26T17:13:26Z
dc.date.accessioned2018-03-29T00:01:48Z
dc.date.available2018-03-29T00:01:48Z
dc.identifierEndocrine Pathology. Humana Press Inc, v. 21, n. 4, n. 242, n. 249, 2010.
dc.identifier1046-3976
dc.identifierWOS:000284846300007
dc.identifier10.1007/s12022-010-9137-4
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/82122
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/82122
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/82122
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1281570
dc.descriptionOur purpose was to evaluate MUC1 clinical utility in the diagnosis and prognosis of thyroid cancer patients. We studied the protein expression of MUC1 in 289 thyroid carcinomas and 121 noncancerous thyroid nodules. There were 41 follicular carcinomas (FC) and 248 papillary thyroid carcinomas (PTC) including 149 classic (CPTC), 20 tall cell (TCPTC) and 79 follicular variants (FVPTC). In addition, we used a quantitative real-time PCR (q-PCR) method to measure MUC1 mRNA expression levels in 108 carcinomas, 23 hyperplasias, and 19 FA. According to their serum Tg levels and other evidences of recurrence/metastasis, the patients were classified as free-of-disease (185 cases) or bad outcome (56 cases, 10 deaths). MUC1 protein was identified in 80.2% PTC; 48.8% FC; 68.3% FVPTC; 70% TCPTC; 21.8% FA; 30% hyperplasias and 6% normal thyroid tissues. MUC1 distinguished benign from malignant thyroid tissues (sensitivity = 89%; specificity = 53%). MUC1 also differentiated FC from FA (p = 0.0083). q-PCR mRNA expression of MUC1 also distinguished malignant from benign nodules (Mann-Whitney test, p < 0.0001). However, neither IHC nor mRNA MUC1 expression was associated with any clinical or pathological feature of aggressiveness or outcome. We suggest that MUC1 expression may help differentiate follicular patterned thyroid lesions.
dc.description21
dc.description4
dc.description242
dc.description249
dc.languageen
dc.publisherHumana Press Inc
dc.publisherTotowa
dc.publisherEUA
dc.relationEndocrine Pathology
dc.relationEndocr. Pathol.
dc.rightsfechado
dc.sourceWeb of Science
dc.subjectMUC1
dc.subjectThyroid cancer
dc.subjectBenign nodules
dc.subjectFollicular carcinomas
dc.subjectFollicular adenomas
dc.subjectSquamous-cell Carcinoma
dc.subjectPapillary Carcinoma
dc.subjectMucin
dc.subjectCancer
dc.subjectGene
dc.subjectMetastasis
dc.subjectCytology
dc.subjectProtein
dc.subjectBenign
dc.subjectMarker
dc.titleMuc-1 Expression May Help Characterize Thyroid Nodules but Does Not Predict Patients' Outcome
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución